Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 265,900 shares, a growth of 124.8% from the April 30th total of 118,300 shares. Based on an average trading volume of 181,200 shares, the short-interest ratio is currently 1.5 days. Approximately 3.9% of the company’s stock are short sold.

Shares of NASDAQ OSMT traded down $0.08 during midday trading on Monday, hitting $3.07. The stock had a trading volume of 405 shares, compared to its average volume of 149,930. The firm’s 50 day moving average is $2.99. The stock has a market cap of $162.29 million and a P/E ratio of -6.06. Osmotica Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $9.90. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $57.13 million for the quarter, compared to analysts’ expectations of $53.58 million. Sell-side analysts expect that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current fiscal year.

Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 25th. Wells Fargo & Co set a $14.00 price objective on shares of Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 28th. Finally, Barclays assumed coverage on shares of Osmotica Pharmaceuticals in a research note on Tuesday, June 11th. They set an “overweight” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $14.00.

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Osmotica Pharmaceuticals in the first quarter worth approximately $45,000. Deutsche Bank AG purchased a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at approximately $111,000. Sofinnova Investments Inc. purchased a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at approximately $1,961,000. Millennium Management LLC purchased a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at approximately $2,568,000. Finally, Great Point Partners LLC purchased a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at approximately $11,625,000. Hedge funds and other institutional investors own 11.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://theolympiareport.com/2019/06/17/osmotica-pharmaceuticals-plc-nasdaqosmt-sees-large-increase-in-short-interest.html.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Story: How to execute a trade ex-dividend strategy?

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.